PMAM
ALNY icon

Picton Mahoney Asset Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Picton Mahoney Asset Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-932
Closed -$371K – 1248
2025
Q4 		$371K Buy
+932
New +$412K ﹤0.01% 714

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Picton Mahoney Asset Management's ALNY Position: Q1 2026 in Review

Picton Mahoney Asset Management sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2026, closing a stake of 932 shares — an estimated $371K sold.

Picton Mahoney Asset Management first reported a position in ALNY in Q4 2025 and held it in 1 quarter. The position peaked at $371K in Q4 2025. 787 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • Picton Mahoney Asset Management reported no remaining Alnylam Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Picton Mahoney Asset Management sold 932 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $371K.
  • Picton Mahoney Asset Management first reported a position in Alnylam Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • Picton Mahoney Asset Management's Alnylam Pharmaceuticals position peaked at $371K in Q4 2025.
  • 787 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Picton Mahoney Asset Management's 13F filing for Q1 2026, filed 13 May 2026.